Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma
Sponsor: Henan Cancer Hospital
This PHASE2 trial investigates Central Nervous System Lymphoma and is currently actively recruiting participants. Henan Cancer Hospital leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
May 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2022 — Jun 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Feb 2022 — Mar 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henan Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .